- Home
- KRYS vs SPR Comparison
KRYS vs SPR Comparison
Compare KRYS & SPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRYS
- SPR
- Stock Information
- Founded
- KRYS 2015
- SPR 1927
- Country
- KRYS United States
- SPR United States
- Employees
- KRYS N/A
- SPR N/A
- Industry
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- SPR Military/Government/Technical
- Sector
- KRYS Health Care
- SPR Industrials
- Exchange
- KRYS Nasdaq
- SPR Nasdaq
- Market Cap
- KRYS 4.3B
- SPR 4.8B
- IPO Year
- KRYS 2017
- SPR 2006
- Fundamental
- Price
- KRYS $153.22
- SPR $39.82
- Analyst Decision
- KRYS Strong Buy
- SPR Hold
- Analyst Count
- KRYS 11
- SPR 2
- Target Price
- KRYS $204.27
- SPR $38.63
- AVG Volume (30 Days)
- KRYS 273.0K
- SPR 764.7K
- Earning Date
- KRYS 08-04-2025
- SPR 08-08-2025
- Dividend Yield
- KRYS N/A
- SPR N/A
- EPS Growth
- KRYS 109.01
- SPR N/A
- EPS
- KRYS 4.16
- SPR N/A
- Revenue
- KRYS $333,448,000.00
- SPR $6,135,600,000.00
- Revenue This Year
- KRYS $40.10
- SPR $25.26
- Revenue Next Year
- KRYS $49.73
- SPR $14.17
- P/E Ratio
- KRYS $36.72
- SPR N/A
- Revenue Growth
- KRYS 247.53
- SPR N/A
- 52 Week Low
- KRYS $122.80
- SPR $27.00
- 52 Week High
- KRYS $212.06
- SPR $42.33
- Technical
- Relative Strength Index (RSI)
- KRYS 60.29
- SPR 50.90
- Support Level
- KRYS $147.35
- SPR $40.27
- Resistance Level
- KRYS $154.99
- SPR $42.33
- Average True Range (ATR)
- KRYS 4.27
- SPR 0.84
- MACD
- KRYS 0.11
- SPR -0.13
- Stochastic Oscillator
- KRYS 69.85
- SPR 7.38
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
About SPR Spirit Aerosystems Holdings Inc.
Spirit AeroSystems manufactures aerostructures, particularly fuselages, cockpits, wing sections, engine pylons, and nacelles for commercial and military aircraft. The company was spun out of Boeing in 2005 to become the largest independent supplier of aerostructures for commercial aircraft. Boeing and Airbus are the firm's primary customers—Boeing represented roughly 60% and Airbus roughly 20% of revenue in recent years. The company is highly exposed to Boeing's beleaguered 737 program, which accounts for nearly half the company's revenue. The company plans to be acquired by and reintegrated into Boeing in mid-2025.